Amneal Pharmaceuticals acquires India’s global injectable firm Puniska Healthcare

#Pharmaceuticals #Amneal #Injectable #Acquisitions #Puniska #PharmaIndustry

Source: Amneal Pharmaceuticals

Significantly enhances its manufacturing capabilities and capacity with the acquisition

November 2021: US based Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has announced it has acquired Puniska Healthcare Pvt. Ltd. The acquisition significantly enhances Amneal’s injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets.

Puniska includes a 293,000 sq. ft., state-of-the-art manufacturing facility in Ahmedabad, India, with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag line. The acquisition also brings to Amneal approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialization.

“We are pleased to announce the acquisition of Puniska, and we welcome the Puniska team to the Amneal family. This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in India, as we look to become a leading player in the global injectables market,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “Puniska’s ability to manufacture high volume and complex products will enable Amneal to build on our robust portfolio and pipeline and contribute to the rapid growth in our injectables business, which we project will more than double by 2025.” Puniska acquisition has a total value of US$93 million, or approximately Rs.700 crore.

Amneal continues to invest and expand in India

Since establishing local operations in 2008, Amneal has built a large and growing presence in India through over US$300 million, or over Rs.2,200 crore rupee, of capital investments and acquisitions. With Puniska, the Company employees more than 4,500 talented employees to support its core global manufacturing and R&D functions across eight facilities in India. This acquisition furthers the Company’s commitment to and underscores its confidence in India as it continues to expand in the country and make meaningful contributions to local economies.